Loading…
Reported covered position: Legislative Assistant, Rep. Cass Ballenger; Legislative Assistant, Rep. Howard Coble; Legislative Director, Rep. Howard Coble
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Advocate on drug pricing proposals, expanding access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Engage on pharmaceutical policy as it relates to payments under the 340B program. Highlight Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatments for COVID-19 (2019 Novel Coronavirus), including: manufacturing, clinical trials, reimbursement and coverage of Veklury (remdesivir). H.R.1319 - American Rescue Plan Act of 2021
Elijah E. Cummings Lower Drug Costs Now Act
Client: GILEAD SCIENCES INC · Firm: GILEAD SCIENCES, INC.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
GILEAD SCIENCES INC via GILEAD SCIENCES, INC.
2026 · third_quarter · 3A
Advocate for provisions modifying the Inflation Reduction Act and other drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, oncology products, and COVID-19 therapies and prevention including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules, including those related to payments in Medicare, Medicaid drug rebates, and proposed CMMI demonstrations.
Advocate on drug pricing proposals. Proposals to expand access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Advocate in favor of 340B program reforms and changes. Issues related to developing treatments and therapies, including: manufacturing, clinical trials, reimbursement and coverage.
Source: Senate LDA
Advocate on drug pricing proposals, expanding access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Engage on pharmaceutical policy as it relates to payments under the 340B program. Highlight Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatments for COVID-19 (2019 Novel Coronavirus), including: manufacturing, clinical trials, reimbursement and coverage of Veklury (remdesivir). H.R.3 - Elijah E. Cummings Lower Drug Costs Now Act
Consolidated Appropriations Act, 2021
Client: GILEAD SCIENCES INC · Firm: GILEAD SCIENCES, INC.
Administration drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products, including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules related to Notice of Benefit and Payment Parameters (NBPP), hospital inpatient payments, and Value-Based Purchasing arrangements. H.R.3 - Lower Drug Costs Now Act H.R.19 - Lower Costs, More Cures Act of 2019 H.R.259 - Medicaid Extenders Act of 2019 H.R. 7647 - To provide for a COVID-19-related delay regarding annual limitation on cost-sharing for group health plans and individual and small group health insurance coverage S.2543 - The Prescription Drug Pricing Reduction Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 H.R. 133 - Consolidated Appropriations Act, 2021
Administration drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products. Medicare Part D reform and benefit redesign. 2021 Notice of Benefit and Payment Parameters (NBPP) proposed rule and CMS rules related to hospital inpatient payments. S.2543 - The Prescription Drug Pricing Reduction Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 H.R.3 - Lower Drug Costs Now Act of 2019 H.R.19 - Lower Costs, More Cures Act of 2019 H.R.259 - Medicaid Extenders Act of 2019
Administration drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products. Medicare Part D reform and benefit redesign. 2021 Notice of Benefit and Payment Parameters (NBPP) proposed rule and CMS rules related to hospital inpatient payments and value-based purchasing arrangements. S.2543 - The Prescription Drug Pricing Reduction Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 H.R.3 - Lower Drug Costs Now Act of 2019 H.R.19 - Lower Costs, More Cures Act of 2019 H.R.259 - Medicaid Extenders Act of 2019
Administration drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products. Medicare Part D reform and benefit redesign. CMS rules related to Notice of Benefit and Payment Parameters (NBPP), hospital inpatient payments, and value-based purchasing arrangements. H.R.3 - Lower Drug Costs Now Act of 2019 H.R.19 - Lower Costs, More Cures Act of 2019 H.R.259 - Medicaid Extenders Act of 2019 H.R. 7647 - To provide for a COVID-19-related delay regarding annual limitation on cost-sharing for group health plans and individual and small group health insurance coverage S.2543 - The Prescription Drug Pricing Reduction Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019
Administration drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products, including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules related to Notice of Benefit and Payment Parameters (NBPP), hospital inpatient payments, and Value-Based Purchasing arrangements. H.R.3 - Lower Drug Costs Now Act H.R.19 - Lower Costs, More Cures Act of 2019 H.R.259 - Medicaid Extenders Act of 2019 H.R. 7647 - To provide for a COVID-19-related delay regarding annual limitation on cost-sharing for group health plans and individual and small group health insurance coverage S.2543 - The Prescription Drug Pricing Reduction Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 H.R. 133 - Consolidated Appropriations Act, 2021
Administration drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products. Medicare Part D reform and benefit redesign. 2021 Notice of Benefit and Payment Parameters (NBPP) proposed rule and CMS rules related to hospital inpatient payments and value-based purchasing arrangements. S.2543 - The Prescription Drug Pricing Reduction Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 H.R.3 - Lower Drug Costs Now Act of 2019 H.R.19 - Lower Costs, More Cures Act of 2019 H.R.259 - Medicaid Extenders Act of 2019
Administration drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products. Medicare Part D reform and benefit redesign. CMS rules related to Notice of Benefit and Payment Parameters (NBPP), hospital inpatient payments, and value-based purchasing arrangements. H.R.3 - Lower Drug Costs Now Act of 2019 H.R.19 - Lower Costs, More Cures Act of 2019 H.R.259 - Medicaid Extenders Act of 2019 H.R. 7647 - To provide for a COVID-19-related delay regarding annual limitation on cost-sharing for group health plans and individual and small group health insurance coverage S.2543 - The Prescription Drug Pricing Reduction Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019
Administration drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products, including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules related to Notice of Benefit and Payment Parameters (NBPP), hospital inpatient payments, and Value-Based Purchasing arrangements. H.R.3 - Lower Drug Costs Now Act H.R.19 - Lower Costs, More Cures Act of 2019 H.R.259 - Medicaid Extenders Act of 2019 H.R. 7647 - To provide for a COVID-19-related delay regarding annual limitation on cost-sharing for group health plans and individual and small group health insurance coverage S.2543 - The Prescription Drug Pricing Reduction Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 H.R. 133 - Consolidated Appropriations Act, 2021
Administration drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products. Medicare Part D reform and benefit redesign. 2021 Notice of Benefit and Payment Parameters (NBPP) proposed rule and CMS rules related to hospital inpatient payments. S.2543 - The Prescription Drug Pricing Reduction Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 H.R.3 - Lower Drug Costs Now Act of 2019 H.R.19 - Lower Costs, More Cures Act of 2019 H.R.259 - Medicaid Extenders Act of 2019
Elijah E. Cummings Lower Drug Costs Now Act
Client: GILEAD SCIENCES INC · Firm: GILEAD SCIENCES, INC.
Expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. Highlighting Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatment for COVID-19 (2019 Novel Coronavirus), including: clinical trials, expanded access, compassionate use program, emergency use authorization, donation, distribution and allocation of remdesivir. H.R.6201 - Families First Coronavirus Response Act H.R.748 / S.3548 - CARES Act H.R.3 - Lower Drug Costs Now Act of 2019 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act H.R.6800 - The Heroes Act
Elijah E. Cummings Lower Drug Costs Now Act
Client: GILEAD SCIENCES INC · Firm: GILEAD SCIENCES, INC.
Administration drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products. Medicare Part D reform and benefit redesign. 2021 Notice of Benefit and Payment Parameters (NBPP) proposed rule and CMS rules related to hospital inpatient payments. S.2543 - The Prescription Drug Pricing Reduction Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 H.R.3 - Lower Drug Costs Now Act of 2019 H.R.19 - Lower Costs, More Cures Act of 2019 H.R.259 - Medicaid Extenders Act of 2019
Elijah E. Cummings Lower Drug Costs Now Act
Client: GILEAD SCIENCES INC · Firm: GILEAD SCIENCES, INC.
Administration drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products. Medicare Part D reform and benefit redesign. 2021 Notice of Benefit and Payment Parameters (NBPP) proposed rule and CMS rules related to hospital inpatient payments and value-based purchasing arrangements. S.2543 - The Prescription Drug Pricing Reduction Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 H.R.3 - Lower Drug Costs Now Act of 2019 H.R.19 - Lower Costs, More Cures Act of 2019 H.R.259 - Medicaid Extenders Act of 2019
Elijah E. Cummings Lower Drug Costs Now Act
Client: GILEAD SCIENCES INC · Firm: GILEAD SCIENCES, INC.
Administration drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products. Medicare Part D reform and benefit redesign. CMS rules related to Notice of Benefit and Payment Parameters (NBPP), hospital inpatient payments, and value-based purchasing arrangements. H.R.3 - Lower Drug Costs Now Act of 2019 H.R.19 - Lower Costs, More Cures Act of 2019 H.R.259 - Medicaid Extenders Act of 2019 H.R. 7647 - To provide for a COVID-19-related delay regarding annual limitation on cost-sharing for group health plans and individual and small group health insurance coverage S.2543 - The Prescription Drug Pricing Reduction Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019
Elijah E. Cummings Lower Drug Costs Now Act
Client: GILEAD SCIENCES INC · Firm: GILEAD SCIENCES, INC.
Expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. Issues related to developing new treatment for COVID-19 (2019 Novel Coronavirus). H.R.6201 - Families First Coronavirus Response Act H.R.748 / S.3548 - CARES Act H.R.3 - Lower Drug Costs Now Act of 2019 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act
Elijah E. Cummings Lower Drug Costs Now Act
Client: GILEAD SCIENCES INC · Firm: GILEAD SCIENCES, INC.
Expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. Highlighting Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatment for COVID-19 (2019 Novel Coronavirus), including: clinical trials, expanded access, compassionate use program, emergency use authorization, donation, distribution and allocation, and reimbursement of Veklury (remdesivir). H.R.6201 - Families First Coronavirus Response Act H.R.748 / S.3548 - CARES Act H.R.3 - Lower Drug Costs Now Act of 2019 H.R.6800 - The Heroes Act H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act
Elijah E. Cummings Lower Drug Costs Now Act
Client: GILEAD SCIENCES INC · Firm: GILEAD SCIENCES, INC.
Administration drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products, including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules related to Notice of Benefit and Payment Parameters (NBPP), hospital inpatient payments, and Value-Based Purchasing arrangements. H.R.3 - Lower Drug Costs Now Act H.R.19 - Lower Costs, More Cures Act of 2019 H.R.259 - Medicaid Extenders Act of 2019 H.R. 7647 - To provide for a COVID-19-related delay regarding annual limitation on cost-sharing for group health plans and individual and small group health insurance coverage S.2543 - The Prescription Drug Pricing Reduction Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 H.R. 133 - Consolidated Appropriations Act, 2021
Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020
Client: GILEAD SCIENCES INC · Firm: GILEAD SCIENCES, INC.
Expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. Highlighting Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatment for COVID-19 (2019 Novel Coronavirus), including: clinical trials, expanded access, compassionate use program, emergency use authorization, donation, distribution and allocation, and reimbursement of Veklury (remdesivir). H.R.6201 - Families First Coronavirus Response Act H.R.748 / S.3548 - CARES Act H.R.3 - Lower Drug Costs Now Act of 2019 H.R.6800 - The Heroes Act H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act
Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020
Client: GILEAD SCIENCES INC · Firm: GILEAD SCIENCES, INC.
Advocate on drug pricing proposals, expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. Highlighting Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatment for COVID-19 (2019 Novel Coronavirus), including: clinical trials, expanded access, compassionate use program, emergency use authorization, donation, distribution and allocation, and reimbursement of Veklury (remdesivir). H.R.6201 - Families First Coronavirus Response Act S.3548 - CARES Act H.R.6800 - The Heroes Act H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act
Families First Coronavirus Response Act
Client: GILEAD SCIENCES INC · Firm: GILEAD SCIENCES, INC.
Expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. Highlighting Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatment for COVID-19 (2019 Novel Coronavirus), including: clinical trials, expanded access, compassionate use program, emergency use authorization, donation, distribution and allocation of remdesivir. H.R.6201 - Families First Coronavirus Response Act H.R.748 / S.3548 - CARES Act H.R.3 - Lower Drug Costs Now Act of 2019 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act H.R.6800 - The Heroes Act
Families First Coronavirus Response Act
Client: GILEAD SCIENCES INC · Firm: GILEAD SCIENCES, INC.
Expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. Issues related to developing new treatment for COVID-19 (2019 Novel Coronavirus). H.R.6201 - Families First Coronavirus Response Act H.R.748 / S.3548 - CARES Act H.R.3 - Lower Drug Costs Now Act of 2019 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act
Families First Coronavirus Response Act
Client: GILEAD SCIENCES INC · Firm: GILEAD SCIENCES, INC.
Advocate on drug pricing proposals, expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. Highlighting Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatment for COVID-19 (2019 Novel Coronavirus), including: clinical trials, expanded access, compassionate use program, emergency use authorization, donation, distribution and allocation, and reimbursement of Veklury (remdesivir). H.R.6201 - Families First Coronavirus Response Act S.3548 - CARES Act H.R.6800 - The Heroes Act H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act
Families First Coronavirus Response Act
Client: GILEAD SCIENCES INC · Firm: GILEAD SCIENCES, INC.
Expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. Highlighting Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatment for COVID-19 (2019 Novel Coronavirus), including: clinical trials, expanded access, compassionate use program, emergency use authorization, donation, distribution and allocation, and reimbursement of Veklury (remdesivir). H.R.6201 - Families First Coronavirus Response Act H.R.748 / S.3548 - CARES Act H.R.3 - Lower Drug Costs Now Act of 2019 H.R.6800 - The Heroes Act H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act
Expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. Highlighting Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatment for COVID-19 (2019 Novel Coronavirus), including: clinical trials, expanded access, compassionate use program, emergency use authorization, donation, distribution and allocation of remdesivir. H.R.6201 - Families First Coronavirus Response Act H.R.748 / S.3548 - CARES Act H.R.3 - Lower Drug Costs Now Act of 2019 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act H.R.6800 - The Heroes Act
Expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. Highlighting Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatment for COVID-19 (2019 Novel Coronavirus), including: clinical trials, expanded access, compassionate use program, emergency use authorization, donation, distribution and allocation, and reimbursement of Veklury (remdesivir). H.R.6201 - Families First Coronavirus Response Act H.R.748 / S.3548 - CARES Act H.R.3 - Lower Drug Costs Now Act of 2019 H.R.6800 - The Heroes Act H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act
Advocate on drug pricing proposals, expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. Highlighting Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatment for COVID-19 (2019 Novel Coronavirus), including: clinical trials, expanded access, compassionate use program, emergency use authorization, donation, distribution and allocation, and reimbursement of Veklury (remdesivir). H.R.6201 - Families First Coronavirus Response Act S.3548 - CARES Act H.R.6800 - The Heroes Act H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act
Expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. Highlighting Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatment for COVID-19 (2019 Novel Coronavirus), including: clinical trials, expanded access, compassionate use program, emergency use authorization, donation, distribution and allocation of remdesivir. H.R.6201 - Families First Coronavirus Response Act H.R.748 / S.3548 - CARES Act H.R.3 - Lower Drug Costs Now Act of 2019 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act H.R.6800 - The Heroes Act
Expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. Highlighting Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatment for COVID-19 (2019 Novel Coronavirus), including: clinical trials, expanded access, compassionate use program, emergency use authorization, donation, distribution and allocation, and reimbursement of Veklury (remdesivir). H.R.6201 - Families First Coronavirus Response Act H.R.748 / S.3548 - CARES Act H.R.3 - Lower Drug Costs Now Act of 2019 H.R.6800 - The Heroes Act H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act
Expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. Issues related to developing new treatment for COVID-19 (2019 Novel Coronavirus). H.R.6201 - Families First Coronavirus Response Act H.R.748 / S.3548 - CARES Act H.R.3 - Lower Drug Costs Now Act of 2019 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act
To provide for a COVID-19-related delay regarding annual limitation on cost-sharing for group health plans and individual and small group health insurance coverage.
Client: GILEAD SCIENCES INC · Firm: GILEAD SCIENCES, INC.
Administration drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products. Medicare Part D reform and benefit redesign. CMS rules related to Notice of Benefit and Payment Parameters (NBPP), hospital inpatient payments, and value-based purchasing arrangements. H.R.3 - Lower Drug Costs Now Act of 2019 H.R.19 - Lower Costs, More Cures Act of 2019 H.R.259 - Medicaid Extenders Act of 2019 H.R. 7647 - To provide for a COVID-19-related delay regarding annual limitation on cost-sharing for group health plans and individual and small group health insurance coverage S.2543 - The Prescription Drug Pricing Reduction Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019
To provide for a COVID-19-related delay regarding annual limitation on cost-sharing for group health plans and individual and small group health insurance coverage.
Client: GILEAD SCIENCES INC · Firm: GILEAD SCIENCES, INC.
Administration drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products, including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules related to Notice of Benefit and Payment Parameters (NBPP), hospital inpatient payments, and Value-Based Purchasing arrangements. H.R.3 - Lower Drug Costs Now Act H.R.19 - Lower Costs, More Cures Act of 2019 H.R.259 - Medicaid Extenders Act of 2019 H.R. 7647 - To provide for a COVID-19-related delay regarding annual limitation on cost-sharing for group health plans and individual and small group health insurance coverage S.2543 - The Prescription Drug Pricing Reduction Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 H.R. 133 - Consolidated Appropriations Act, 2021
Prescription Drug Pricing Reduction Act of 2019
Client: GILEAD SCIENCES INC · Firm: GILEAD SCIENCES, INC.
Advocate on drug pricing proposals, expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. Highlighting Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatment for COVID-19 (2019 Novel Coronavirus), including: clinical trials, expanded access, compassionate use program, emergency use authorization, donation, distribution and allocation, and reimbursement of Veklury (remdesivir). H.R.6201 - Families First Coronavirus Response Act S.3548 - CARES Act H.R.6800 - The Heroes Act H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act
Prescription Drug Pricing Reduction Act of 2019
Client: GILEAD SCIENCES INC · Firm: GILEAD SCIENCES, INC.
Expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. Highlighting Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatment for COVID-19 (2019 Novel Coronavirus), including: clinical trials, expanded access, compassionate use program, emergency use authorization, donation, distribution and allocation, and reimbursement of Veklury (remdesivir). H.R.6201 - Families First Coronavirus Response Act H.R.748 / S.3548 - CARES Act H.R.3 - Lower Drug Costs Now Act of 2019 H.R.6800 - The Heroes Act H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act
Prescription Drug Pricing Reduction Act of 2019
Client: GILEAD SCIENCES INC · Firm: GILEAD SCIENCES, INC.
Administration drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products, including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules related to Notice of Benefit and Payment Parameters (NBPP), hospital inpatient payments, and Value-Based Purchasing arrangements. H.R.3 - Lower Drug Costs Now Act H.R.19 - Lower Costs, More Cures Act of 2019 H.R.259 - Medicaid Extenders Act of 2019 H.R. 7647 - To provide for a COVID-19-related delay regarding annual limitation on cost-sharing for group health plans and individual and small group health insurance coverage S.2543 - The Prescription Drug Pricing Reduction Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 H.R. 133 - Consolidated Appropriations Act, 2021
Prescription Drug Pricing Reduction Act of 2019
Client: GILEAD SCIENCES INC · Firm: GILEAD SCIENCES, INC.
Expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. Highlighting Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatment for COVID-19 (2019 Novel Coronavirus), including: clinical trials, expanded access, compassionate use program, emergency use authorization, donation, distribution and allocation of remdesivir. H.R.6201 - Families First Coronavirus Response Act H.R.748 / S.3548 - CARES Act H.R.3 - Lower Drug Costs Now Act of 2019 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act H.R.6800 - The Heroes Act
Prescription Drug Pricing Reduction Act of 2019
Client: GILEAD SCIENCES INC · Firm: GILEAD SCIENCES, INC.
Administration drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products. Medicare Part D reform and benefit redesign. 2021 Notice of Benefit and Payment Parameters (NBPP) proposed rule and CMS rules related to hospital inpatient payments. S.2543 - The Prescription Drug Pricing Reduction Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 H.R.3 - Lower Drug Costs Now Act of 2019 H.R.19 - Lower Costs, More Cures Act of 2019 H.R.259 - Medicaid Extenders Act of 2019
Prescription Drug Pricing Reduction Act of 2019
Client: GILEAD SCIENCES INC · Firm: GILEAD SCIENCES, INC.
Administration drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products. Medicare Part D reform and benefit redesign. 2021 Notice of Benefit and Payment Parameters (NBPP) proposed rule and CMS rules related to hospital inpatient payments and value-based purchasing arrangements. S.2543 - The Prescription Drug Pricing Reduction Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 H.R.3 - Lower Drug Costs Now Act of 2019 H.R.19 - Lower Costs, More Cures Act of 2019 H.R.259 - Medicaid Extenders Act of 2019
Prescription Drug Pricing Reduction Act of 2019
Client: GILEAD SCIENCES INC · Firm: GILEAD SCIENCES, INC.
Administration drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products. Medicare Part D reform and benefit redesign. CMS rules related to Notice of Benefit and Payment Parameters (NBPP), hospital inpatient payments, and value-based purchasing arrangements. H.R.3 - Lower Drug Costs Now Act of 2019 H.R.19 - Lower Costs, More Cures Act of 2019 H.R.259 - Medicaid Extenders Act of 2019 H.R. 7647 - To provide for a COVID-19-related delay regarding annual limitation on cost-sharing for group health plans and individual and small group health insurance coverage S.2543 - The Prescription Drug Pricing Reduction Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019
Prescription Drug Pricing Reduction Act of 2019
Client: GILEAD SCIENCES INC · Firm: GILEAD SCIENCES, INC.
Expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. Issues related to developing new treatment for COVID-19 (2019 Novel Coronavirus). H.R.6201 - Families First Coronavirus Response Act H.R.748 / S.3548 - CARES Act H.R.3 - Lower Drug Costs Now Act of 2019 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act
Encouraging Innovative Benefit Design to Lower Costs for Seniors Act
Client: GILEAD SCIENCES INC · Firm: GILEAD SCIENCES, INC.
Advocate on drug pricing proposals, expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. Highlighting Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatment for COVID-19 (2019 Novel Coronavirus), including: clinical trials, expanded access, compassionate use program, emergency use authorization, donation, distribution and allocation, and reimbursement of Veklury (remdesivir). H.R.6201 - Families First Coronavirus Response Act S.3548 - CARES Act H.R.6800 - The Heroes Act H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act
Encouraging Innovative Benefit Design to Lower Costs for Seniors Act
Client: GILEAD SCIENCES INC · Firm: GILEAD SCIENCES, INC.
Expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. Highlighting Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatment for COVID-19 (2019 Novel Coronavirus), including: clinical trials, expanded access, compassionate use program, emergency use authorization, donation, distribution and allocation, and reimbursement of Veklury (remdesivir). H.R.6201 - Families First Coronavirus Response Act H.R.748 / S.3548 - CARES Act H.R.3 - Lower Drug Costs Now Act of 2019 H.R.6800 - The Heroes Act H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act
Encouraging Innovative Benefit Design to Lower Costs for Seniors Act
Client: GILEAD SCIENCES INC · Firm: GILEAD SCIENCES, INC.
Expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. Highlighting Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatment for COVID-19 (2019 Novel Coronavirus), including: clinical trials, expanded access, compassionate use program, emergency use authorization, donation, distribution and allocation of remdesivir. H.R.6201 - Families First Coronavirus Response Act H.R.748 / S.3548 - CARES Act H.R.3 - Lower Drug Costs Now Act of 2019 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act H.R.6800 - The Heroes Act
Encouraging Innovative Benefit Design to Lower Costs for Seniors Act
Client: GILEAD SCIENCES INC · Firm: GILEAD SCIENCES, INC.
Expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. Issues related to developing new treatment for COVID-19 (2019 Novel Coronavirus). H.R.6201 - Families First Coronavirus Response Act H.R.748 / S.3548 - CARES Act H.R.3 - Lower Drug Costs Now Act of 2019 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act
Administration drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products, including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules related to Notice of Benefit and Payment Parameters (NBPP), hospital inpatient payments, and Value-Based Purchasing arrangements. H.R.3 - Lower Drug Costs Now Act H.R.19 - Lower Costs, More Cures Act of 2019 H.R.259 - Medicaid Extenders Act of 2019 H.R. 7647 - To provide for a COVID-19-related delay regarding annual limitation on cost-sharing for group health plans and individual and small group health insurance coverage S.2543 - The Prescription Drug Pricing Reduction Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 H.R. 133 - Consolidated Appropriations Act, 2021
Administration drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products. Medicare Part D reform and benefit redesign. 2021 Notice of Benefit and Payment Parameters (NBPP) proposed rule and CMS rules related to hospital inpatient payments. S.2543 - The Prescription Drug Pricing Reduction Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 H.R.3 - Lower Drug Costs Now Act of 2019 H.R.19 - Lower Costs, More Cures Act of 2019 H.R.259 - Medicaid Extenders Act of 2019
Administration drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products. Medicare Part D reform and benefit redesign. 2021 Notice of Benefit and Payment Parameters (NBPP) proposed rule and CMS rules related to hospital inpatient payments and value-based purchasing arrangements. S.2543 - The Prescription Drug Pricing Reduction Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 H.R.3 - Lower Drug Costs Now Act of 2019 H.R.19 - Lower Costs, More Cures Act of 2019 H.R.259 - Medicaid Extenders Act of 2019
Administration drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products. Medicare Part D reform and benefit redesign. CMS rules related to Notice of Benefit and Payment Parameters (NBPP), hospital inpatient payments, and value-based purchasing arrangements. H.R.3 - Lower Drug Costs Now Act of 2019 H.R.19 - Lower Costs, More Cures Act of 2019 H.R.259 - Medicaid Extenders Act of 2019 H.R. 7647 - To provide for a COVID-19-related delay regarding annual limitation on cost-sharing for group health plans and individual and small group health insurance coverage S.2543 - The Prescription Drug Pricing Reduction Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019
Advocate on drug pricing proposals, expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. Highlighting Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatment for COVID-19 (2019 Novel Coronavirus), including: clinical trials, expanded access, compassionate use program, emergency use authorization, donation, distribution and allocation, and reimbursement of Veklury (remdesivir). H.R.6201 - Families First Coronavirus Response Act S.3548 - CARES Act H.R.6800 - The Heroes Act H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act
Expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. Highlighting Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatment for COVID-19 (2019 Novel Coronavirus), including: clinical trials, expanded access, compassionate use program, emergency use authorization, donation, distribution and allocation, and reimbursement of Veklury (remdesivir). H.R.6201 - Families First Coronavirus Response Act H.R.748 / S.3548 - CARES Act H.R.3 - Lower Drug Costs Now Act of 2019 H.R.6800 - The Heroes Act H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act
Expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. Highlighting Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatment for COVID-19 (2019 Novel Coronavirus), including: clinical trials, expanded access, compassionate use program, emergency use authorization, donation, distribution and allocation of remdesivir. H.R.6201 - Families First Coronavirus Response Act H.R.748 / S.3548 - CARES Act H.R.3 - Lower Drug Costs Now Act of 2019 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act H.R.6800 - The Heroes Act
Expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. Issues related to developing new treatment for COVID-19 (2019 Novel Coronavirus). H.R.6201 - Families First Coronavirus Response Act H.R.748 / S.3548 - CARES Act H.R.3 - Lower Drug Costs Now Act of 2019 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
GILEAD SCIENCES INC via GILEAD SCIENCES, INC.
2026 · third_quarter · Q3
Advocate on drug pricing proposals. Proposals to expand access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Advocate in favor of 340B program reforms and changes. Issues related to developing treatments and therapies, including: manufacturing, clinical trials, reimbursement and coverage.
Advocate for provisions modifying the Inflation Reduction Act and other drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, oncology products, and COVID-19 therapies and prevention including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules, including those related to payments in Medicare, Medicaid drug rebates, and proposed CMMI demonstrations.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
GILEAD SCIENCES INC via GILEAD SCIENCES, INC.
2026 · second_quarter · Q2
Advocate on drug pricing proposals. Proposals to expand access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Advocate in favor of 340B program reforms and changes. Issues related to developing treatments and therapies, including: manufacturing, clinical trials, reimbursement and coverage.
Advocate for provisions modifying the Inflation Reduction Act and other drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, oncology products, and COVID-19 therapies and prevention including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules, including those related to payments in Medicare, Medicaid drug rebates, and proposed CMMI demonstrations.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
GILEAD SCIENCES INC via GILEAD SCIENCES, INC.
2026 · first_quarter · Q1
Advocate on drug pricing proposals. Proposals to expand access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Advocate in favor of 340B program reforms and changes. Issues related to developing treatments and therapies, including: manufacturing, clinical trials, reimbursement and coverage.
Advocate for provisions modifying the Inflation Reduction Act and other drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, oncology products, and COVID-19 therapies and prevention including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules, including those related to payments in Medicare, Medicaid drug rebates, and proposed CMMI demonstrations.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
GILEAD SCIENCES INC via GILEAD SCIENCES, INC.
2025 · fourth_quarter · Q4
Advocate on drug pricing proposals and proposals to expand access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Advocate in favor of 340B program reforms and changes. Highlight Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatments and therapies, including: manufacturing, clinical trials, reimbursement and coverage.
Advocate for provisions modifying the Inflation Reduction Act and other drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, oncology products, and COVID-19 therapies and prevention including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules related to hospital inpatient payments, Medicaid Drug Rebate Program, and Value-Based Purchasing arrangements including changes to best price.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
GILEAD SCIENCES INC via GILEAD SCIENCES, INC.
2025 · third_quarter · Q3
Advocate on drug pricing proposals and proposals to expand access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Advocate in favor of 340B program reforms and changes. Highlight Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatments and therapies, including: manufacturing, clinical trials, reimbursement and coverage.
Advocate for provisions modifying the Inflation Reduction Act and other drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, oncology products, and COVID-19 therapies and prevention including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules related to hospital inpatient payments, Medicaid Drug Rebate Program, and Value-Based Purchasing arrangements including changes to best price.
GILEAD SCIENCES INC via GILEAD SCIENCES, INC.
2025 · second_quarter · Q2
Advocate on drug pricing proposals and proposals to expand access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Advocate in favor of 340B program reforms and changes. Highlight Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatments and therapies, including: manufacturing, clinical trials, reimbursement and coverage.
Advocate for provisions modifying the Inflation Reduction Act and other drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, oncology products, and COVID-19 therapies and prevention including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules related to hospital inpatient payments, Medicaid Drug Rebate Program, and Value-Based Purchasing arrangements including changes to best price.
GILEAD SCIENCES INC via GILEAD SCIENCES, INC.
2025 · first_quarter · Q1
Advocate on drug pricing proposals and proposals to expand access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Advocate in favor of 340B program reforms and changes to Notice of Benefit and Payment Parameters (NBPP). Highlight Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatments and therapies, including: manufacturing, clinical trials, reimbursement and coverage.
Advocate for provisions modifying the Inflation Reduction Act. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, oncology products, and COVID-19 therapies and prevention including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules related to hospital inpatient payments, Medicaid Drug Rebate Program, and Value-Based Purchasing arrangements including changes to best price.
GILEAD SCIENCES INC via GILEAD SCIENCES, INC.
2024 · fourth_quarter · Q4
Advocate on drug pricing proposals and proposals to expand access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Advocate in favor of 340B program reforms and changes to Notice of Benefit and Payment Parameters (NBPP). Highlight Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatments and therapies, including: manufacturing, clinical trials, reimbursement and coverage.
Advocate against expansion of drug pricing proposals, including provisions modifying the Inflation Reduction Act. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, oncology products, and COVID-19 therapies and prevention including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules related to hospital inpatient payments, Medicaid Drug Rebate Program, and Value-Based Purchasing arrangements including changes to best price.
GILEAD SCIENCES INC via GILEAD SCIENCES, INC.
2024 · third_quarter · Q3
Advocate against expansion of drug pricing proposals, including provisions modifying the Inflation Reduction Act. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, oncology products, and COVID-19 therapies and prevention including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules related to Notice of Benefit and Payment Parameters (NBPP), hospital inpatient payments, Medicaid Drug Rebate Program, and Value-Based Purchasing arrangements including changes to best price.
Advocate on drug pricing proposals and proposals to expand access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Engage on pharmaceutical policy as it relates to payments under the 340B program. Highlight Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatments and therapies, including: manufacturing, clinical trials, reimbursement and coverage.
GILEAD SCIENCES INC via GILEAD SCIENCES, INC.
2024 · second_quarter · Q2
Advocate against expansion of drug pricing proposals, including provisions modifying the Inflation Reduction Act. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, oncology products, and COVID-19 therapies and prevention including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules related to Notice of Benefit and Payment Parameters (NBPP), hospital inpatient payments, Medicaid Drug Rebate Program, and Value-Based Purchasing arrangements including changes to best price.
Advocate on drug pricing proposals and proposals to expand access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Engage on pharmaceutical policy as it relates to payments under the 340B program. Highlight Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatments and therapies, including: manufacturing, clinical trials, reimbursement and coverage.
GILEAD SCIENCES INC via GILEAD SCIENCES, INC.
2024 · first_quarter · Q1
Advocate against expansion of drug pricing proposals, including provisions modifying the Inflation Reduction Act. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, oncology products, and COVID-19 therapies and prevention including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules related to Notice of Benefit and Payment Parameters (NBPP), hospital inpatient payments, Medicaid Drug Rebate Program, and Value-Based Purchasing arrangements including changes to best price.
Advocate on drug pricing proposals and proposals to expand access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Engage on pharmaceutical policy as it relates to payments under the 340B program. Highlight Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatments for COVID-19 and other viral pathogens, including: manufacturing, clinical trials, reimbursement and coverage.
GILEAD SCIENCES INC via GILEAD SCIENCES, INC.
2023 · fourth_quarter · Q4
Advocate against expansion of drug pricing proposals, including provisions modifying the Inflation Reduction Act. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, oncology products, and COVID-19 therapies including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules related to Notice of Benefit and Payment Parameters (NBPP), hospital inpatient payments, and Value-Based Purchasing arrangements including changes to best price.
Advocate on drug pricing proposals and proposals to expand access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Engage on pharmaceutical policy as it relates to payments under the 340B program. Highlight Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatments for COVID-19 (2019 Novel Coronavirus), including: manufacturing, clinical trials, reimbursement and coverage of Veklury (remdesivir).
GILEAD SCIENCES INC via GILEAD SCIENCES, INC.
2023 · third_quarter · Q3
Advocate against expansion of drug pricing proposals, including provisions modifying the Inflation Reduction Act. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, oncology products, and COVID-19 therapies including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules related to Notice of Benefit and Payment Parameters (NBPP), hospital inpatient payments, and Value-Based Purchasing arrangements including changes to best price.
Advocate on drug pricing proposals and proposals to expand access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Engage on pharmaceutical policy as it relates to payments under the 340B program. Highlight Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatments for COVID-19 (2019 Novel Coronavirus), including: manufacturing, clinical trials, reimbursement and coverage of Veklury (remdesivir).
GILEAD SCIENCES INC via GILEAD SCIENCES, INC.
2023 · second_quarter · Q2
Advocate on drug pricing proposals and proposals to expand access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Engage on pharmaceutical policy as it relates to payments under the 340B program. Highlight Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatments for COVID-19 (2019 Novel Coronavirus), including: manufacturing, clinical trials, reimbursement and coverage of Veklury (remdesivir).
Advocate on drug pricing proposals, including Inflation Reduction Act. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, oncology products, and COVID-19 therapies including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules related to Notice of Benefit and Payment Parameters (NBPP), hospital inpatient payments, and Value-Based Purchasing arrangements including changes to best price.
GILEAD SCIENCES INC via GILEAD SCIENCES, INC.
2023 · first_quarter · Q1
Advocate on drug pricing proposals, including Inflation Reduction Act. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, oncology products, and COVID-19 therapies including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules related to Notice of Benefit and Payment Parameters (NBPP), hospital inpatient payments, and Value-Based Purchasing arrangements including changes to best price.
Advocate on drug pricing proposals and proposals to expand access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Engage on pharmaceutical policy as it relates to payments under the 340B program. Highlight Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatments for COVID-19 (2019 Novel Coronavirus), including: manufacturing, clinical trials, reimbursement and coverage of Veklury (remdesivir).
GILEAD SCIENCES INC via GILEAD SCIENCES, INC.
2022 · third_quarter · 3A
Advocate on drug pricing proposals, including reconciliation legislation. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, oncology products, and COVID-19 therapies including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules related to Notice of Benefit and Payment Parameters (NBPP), hospital inpatient payments, and Value-Based Purchasing arrangements including changes to best price.
Advocate on drug pricing proposals, including reconciliation legislation, and expanding access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Engage on pharmaceutical policy as it relates to payments under the 340B program. Highlight Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatments for COVID-19 (2019 Novel Coronavirus), including: manufacturing, clinical trials, reimbursement and coverage of Veklury (remdesivir). Reauthorization of the Prescription Drug User Fee Act and related issues.
GILEAD SCIENCES INC via GILEAD SCIENCES, INC.
2022 · third_quarter · 3A
Advocate on drug pricing proposals, including reconciliation legislation, and expanding access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Engage on pharmaceutical policy as it relates to payments under the 340B program. Highlight Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatments for COVID-19 (2019 Novel Coronavirus), including: manufacturing, clinical trials, reimbursement and coverage of Veklury (remdesivir). Reauthorization of the Prescription Drug User Fee Act and related issues.
Advocate on drug pricing proposals, including reconciliation legislation. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, oncology products, and COVID-19 therapies including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules related to Notice of Benefit and Payment Parameters (NBPP), hospital inpatient payments, and Value-Based Purchasing arrangements including changes to best price.
GILEAD SCIENCES INC via GILEAD SCIENCES, INC.
2022 · fourth_quarter · 4A
Advocate on drug pricing proposals, including reconciliation legislation. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, oncology products, and COVID-19 therapies including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules related to Notice of Benefit and Payment Parameters (NBPP), hospital inpatient payments, and Value-Based Purchasing arrangements including changes to best price.
Advocate on drug pricing proposals, including reconciliation legislation, and expanding access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Engage on pharmaceutical policy as it relates to payments under the 340B program. Highlight Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatments for COVID-19 (2019 Novel Coronavirus), including: manufacturing, clinical trials, reimbursement and coverage of Veklury (remdesivir). Reauthorization of the Prescription Drug User Fee Act and related issues.
GILEAD SCIENCES INC via GILEAD SCIENCES, INC.
2022 · fourth_quarter · Q4
Advocate on drug pricing proposals, including reconciliation legislation, and expanding access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Engage on pharmaceutical policy as it relates to payments under the 340B program. Highlight Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatments for COVID-19 (2019 Novel Coronavirus), including: manufacturing, clinical trials, reimbursement and coverage of Veklury (remdesivir). Reauthorization of the Prescription Drug User Fee Act and related issues.
Advocate on drug pricing proposals, including reconciliation legislation. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, oncology products, and COVID-19 therapies including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules related to Notice of Benefit and Payment Parameters (NBPP), hospital inpatient payments, and Value-Based Purchasing arrangements including changes to best price.
GILEAD SCIENCES INC via GILEAD SCIENCES, INC.
2022 · third_quarter · Q3
Advocate on drug pricing proposals, including reconciliation legislation, and expanding access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Engage on pharmaceutical policy as it relates to payments under the 340B program. Highlight Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatments for COVID-19 (2019 Novel Coronavirus), including: manufacturing, clinical trials, reimbursement and coverage of Veklury (remdesivir). Reauthorization of the Prescription Drug User Fee Act and related issues.
Advocate on drug pricing proposals, including reconciliation legislation. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, oncology products, and COVID-19 therapies including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules related to Notice of Benefit and Payment Parameters (NBPP), hospital inpatient payments, and Value-Based Purchasing arrangements including changes to best price.
GILEAD SCIENCES INC via GILEAD SCIENCES, INC.
2022 · second_quarter · Q2
Advocate on drug pricing proposals, including reconciliation legislation, and expanding access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Engage on pharmaceutical policy as it relates to payments under the 340B program. Highlight Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatments for COVID-19 (2019 Novel Coronavirus), including: manufacturing, clinical trials, reimbursement and coverage of Veklury (remdesivir). Reauthorization of the Prescription Drug User Fee Act and related issues.
Advocate on drug pricing proposals, including reconciliation legislation. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, oncology products, and COVID-19 therapies including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules related to Notice of Benefit and Payment Parameters (NBPP), hospital inpatient payments, and Value-Based Purchasing arrangements including changes to best price.
GILEAD SCIENCES INC via GILEAD SCIENCES, INC.
2022 · first_quarter · Q1
Advocate on drug pricing proposals, including reconciliation legislation, and expanding access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Engage on pharmaceutical policy as it relates to payments under the 340B program. Highlight Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatments for COVID-19 (2019 Novel Coronavirus), including: manufacturing, clinical trials, reimbursement and coverage of Veklury (remdesivir). Reauthorization of the Prescription Drug User Fee Act and related issues.
Advocate on drug pricing proposals, including reconciliation legislation. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, oncology products, and COVID-19 therapies including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules related to Notice of Benefit and Payment Parameters (NBPP), hospital inpatient payments, and Value-Based Purchasing arrangements including changes to best price.
GILEAD SCIENCES INC via GILEAD SCIENCES, INC.
2021 · fourth_quarter · Q4
Advocate on drug pricing proposals, including reconciliation legislation. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, oncology products, and COVID-19 therapies including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules related to Notice of Benefit and Payment Parameters (NBPP), hospital inpatient payments, and Value-Based Purchasing arrangements.
Advocate on drug pricing proposals, including reconciliation legislation, and expanding access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Engage on pharmaceutical policy as it relates to payments under the 340B program. Highlight Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatments for COVID-19 (2019 Novel Coronavirus), including: manufacturing, clinical trials, reimbursement and coverage of Veklury (remdesivir).
GILEAD SCIENCES INC via GILEAD SCIENCES, INC.
2021 · third_quarter · Q3
Advocate on drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, oncology products, and COVID-19 therapies including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules related to Notice of Benefit and Payment Parameters (NBPP), hospital inpatient payments, and Value-Based Purchasing arrangements.
Advocate on drug pricing proposals, including reconciliation legislation, and expanding access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Engage on pharmaceutical policy as it relates to payments under the 340B program. Highlight Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatments for COVID-19 (2019 Novel Coronavirus), including: manufacturing, clinical trials, reimbursement and coverage of Veklury (remdesivir).
GILEAD SCIENCES INC via GILEAD SCIENCES, INC.
2021 · second_quarter · Q2
Advocate on drug pricing proposals, expanding access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Engage on pharmaceutical policy as it relates to payments under the 340B program. Highlight Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatments for COVID-19 (2019 Novel Coronavirus), including: manufacturing, clinical trials, reimbursement and coverage of Veklury (remdesivir). H.R.3 - Elijah E. Cummings Lower Drug Costs Now Act
Advocate on drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products, including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules related to Notice of Benefit and Payment Parameters (NBPP), hospital inpatient payments, and Value-Based Purchasing arrangements.
GILEAD SCIENCES INC via GILEAD SCIENCES, INC.
2021 · first_quarter · Q1
Advocate on drug pricing proposals, expanding access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Engage on pharmaceutical policy as it relates to payments under the 340B program. Highlight Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatments for COVID-19 (2019 Novel Coronavirus), including: manufacturing, clinical trials, reimbursement and coverage of Veklury (remdesivir). H.R.1319 - American Rescue Plan Act of 2021
Advocate on drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products, including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules related to Notice of Benefit and Payment Parameters (NBPP), hospital inpatient payments, and Value-Based Purchasing arrangements.
GILEAD SCIENCES INC via GILEAD SCIENCES, INC.
2020 · fourth_quarter · Q4
Advocate on drug pricing proposals, expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. Highlighting Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatment for COVID-19 (2019 Novel Coronavirus), including: clinical trials, expanded access, compassionate use program, emergency use authorization, donation, distribution and allocation, and reimbursement of Veklury (remdesivir). H.R.6201 - Families First Coronavirus Response Act S.3548 - CARES Act H.R.6800 - The Heroes Act H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act
GILEAD SCIENCES INC via GILEAD SCIENCES, INC.
2020 · third_quarter · Q3
Expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. Highlighting Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatment for COVID-19 (2019 Novel Coronavirus), including: clinical trials, expanded access, compassionate use program, emergency use authorization, donation, distribution and allocation, and reimbursement of Veklury (remdesivir). H.R.6201 - Families First Coronavirus Response Act H.R.748 / S.3548 - CARES Act H.R.3 - Lower Drug Costs Now Act of 2019 H.R.6800 - The Heroes Act H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act
GILEAD SCIENCES INC via GILEAD SCIENCES, INC.
2020 · second_quarter · Q2
Expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. Highlighting Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatment for COVID-19 (2019 Novel Coronavirus), including: clinical trials, expanded access, compassionate use program, emergency use authorization, donation, distribution and allocation of remdesivir. H.R.6201 - Families First Coronavirus Response Act H.R.748 / S.3548 - CARES Act H.R.3 - Lower Drug Costs Now Act of 2019 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act H.R.6800 - The Heroes Act
Administration drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products. Medicare Part D reform and benefit redesign. 2021 Notice of Benefit and Payment Parameters (NBPP) proposed rule and CMS rules related to hospital inpatient payments and value-based purchasing arrangements. S.2543 - The Prescription Drug Pricing Reduction Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 H.R.3 - Lower Drug Costs Now Act of 2019 H.R.19 - Lower Costs, More Cures Act of 2019 H.R.259 - Medicaid Extenders Act of 2019
GILEAD SCIENCES INC via GILEAD SCIENCES, INC.
2020 · first_quarter · Q1
Administration drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products. Medicare Part D reform and benefit redesign. 2021 Notice of Benefit and Payment Parameters (NBPP) proposed rule and CMS rules related to hospital inpatient payments. S.2543 - The Prescription Drug Pricing Reduction Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 H.R.3 - Lower Drug Costs Now Act of 2019 H.R.19 - Lower Costs, More Cures Act of 2019 H.R.259 - Medicaid Extenders Act of 2019
Expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. Issues related to developing new treatment for COVID-19 (2019 Novel Coronavirus). H.R.6201 - Families First Coronavirus Response Act H.R.748 / S.3548 - CARES Act H.R.3 - Lower Drug Costs Now Act of 2019 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Science & Technology Policy (OSTP), Office of the Vice President of the United States, Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Office of the Vice President of the United States, Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Office of the Vice President of the United States, Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Natl Security Council (NSC), Office of Management & Budget (OMB), Office of the Vice President of the United States, Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Natl Security Council (NSC), Office of Management & Budget (OMB), Office of the Vice President of the United States, Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Natl Security Council (NSC), Office of Management & Budget (OMB), Office of the Vice President of the United States, Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Natl Security Council (NSC), Office of Management & Budget (OMB), Office of the Vice President of the United States, Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Natl Security Council (NSC), Office of Management & Budget (OMB), Office of the Vice President of the United States, Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Natl Security Council (NSC), Office of Management & Budget (OMB), Office of the Vice President of the United States, Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Natl Security Council (NSC), Office of Management & Budget (OMB), Office of the Vice President of the United States, Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Natl Security Council (NSC), Office of Management & Budget (OMB), Office of the Vice President of the United States, Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Natl Security Council (NSC), Office of Management & Budget (OMB), Office of the Vice President of the United States, Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Natl Security Council (NSC), Office of Management & Budget (OMB), Office of the Vice President of the United States, Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Natl Security Council (NSC), Office of Management & Budget (OMB), Office of the Vice President of the United States, Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Office of the Vice President of the United States, Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Office of the Vice President of the United States, Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Office of the Vice President of the United States, Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), White House Office
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Office of the Vice President of the United States, Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), White House Office
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Office of the Vice President of the United States, Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), White House Office
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Office of the Vice President of the United States, Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), White House Office
Administration drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products, including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules related to Notice of Benefit and Payment Parameters (NBPP), hospital inpatient payments, and Value-Based Purchasing arrangements. H.R.3 - Lower Drug Costs Now Act H.R.19 - Lower Costs, More Cures Act of 2019 H.R.259 - Medicaid Extenders Act of 2019 H.R. 7647 - To provide for a COVID-19-related delay regarding annual limitation on cost-sharing for group health plans and individual and small group health insurance coverage S.2543 - The Prescription Drug Pricing Reduction Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 H.R. 133 - Consolidated Appropriations Act, 2021
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Office of the Vice President of the United States, Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), White House Office
Travel waiver issues related to travel bans due to COVID-19.
Administration drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products. Medicare Part D reform and benefit redesign. CMS rules related to Notice of Benefit and Payment Parameters (NBPP), hospital inpatient payments, and value-based purchasing arrangements. H.R.3 - Lower Drug Costs Now Act of 2019 H.R.19 - Lower Costs, More Cures Act of 2019 H.R.259 - Medicaid Extenders Act of 2019 H.R. 7647 - To provide for a COVID-19-related delay regarding annual limitation on cost-sharing for group health plans and individual and small group health insurance coverage S.2543 - The Prescription Drug Pricing Reduction Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), White House Office
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), White House Office
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), White House Office